logo
The Right Way to Wash a Heated Blanket Safely

The Right Way to Wash a Heated Blanket Safely

CNET10-06-2025
Nothing matches the feeling of crawling into a warm bed after a long, tiring day, especially if you have an electric heated blanket. These not only provide targeted warmth but are also cost-effective, eliminating the need to heat the entire room.
Despite their benefits, electric heated blankets come with some concerns, especially for first-time users. Chief among them: How do you wash one? After all, most electric blanket manufacturers recommend washing the blanket before use. If you've been wondering this, too, you're not alone. Several Reddit users share the same concern, having tried various cleaning hacks and ruining a few blankets along the way.
Here's everything you need to know so you can use your heated blanket without worrying. If you're looking for more information about sleep, check out the wellness editors' favorite sleep tips and how to take a nap without ruining your sleep.
Can you wash a heated blanket?
Generally speaking, yes. Most electric blankets are machine washable and can even be dried in the dryer. But before you go toss yours in the next load of laundry, take a moment to read the blanket's care instructions.
Different blankets may have different washing instructions. For example, Sunbeam, a blanket manufacturer, recommends presoaking the blanket and then washing it in cold water and mild soap on delicate for two minutes. Another blanket maker, Sleepme, makes electric blankets with weighted inserts. They recommend removing the insert, then washing only the outer cover on a gentle cycle.
Materials you'll need to wash your heated blanket
Depending on the care instructions, here are some things you may need to wash your electric blanket.
Washer
Dryer or drying rack/clothesline
Laundry detergent
Clean cloths (if needed for stain treating)
How to wash an electric blanket
Washing a heated blanket isn't difficult, but there are usually some things you'll need to do to prepare the blanket for the washing machine. Here are step-by-step instructions to follow.
1. Remove the cords
The electric blankets cords are what allow the electricity to travel from the outlet into the blanket. Electrical cords should not be submerged in water. Damaging the cords could cause the blanket to malfunction or stop working entirely. It's best to remove all connected cords to ensure the blanket isn't damaged.
2. Review the blanket's washing instructions
Somewhere on the blanket or in the information that came with it, there will be washing and drying instructions. They will usually indicate if the blanket can be machine washed or should be hand washed, what washing machine cycle to use, how to dry and even sometimes soap specifications. It's important to read these before laundering the blanket.
If the washing instructions indicate that the blanket must be hand washed, skip ahead to step four.
3. Run on a delicate cycle
Most electric blankets should be washed on a delicate or gentle cycle. This helps to eliminate dislodging or damaging the wiring inside the blanket.
4. Wash by hand
Though most heated blankets can be washed in a washing machine, there may be some that must be hand washed. In that case, remove the cords, and fill your washing tub with cold water and gentle detergent.
After you've soaked the blanket for a bit, use your hands to wash the blanket, similar to how a washing machine agitates. When you're satisfied with the amount of washing done, drain and refill the tub with water to rinse the blanket. Do this until all soap is gone from the blanket. Squeeze excess water out and either lay flat to dry or dry in the machine on low if the care instructions indicate you can do so.
5. Dry the heated blanket
Most electric blankets can be tumble dried on low in the dryer. Be sure to dry your blanket according to the instructions provided by the manufacturer. If the blanket must be air-dried, try laying it between two towels to soak up excess water and then lay or hang it flat to dry. You might be tempted to wring out excess water by twisting the blanket, but do not do this as it may cause damage to the internal wiring.How often should you wash a heated blanket?
How often you should wash your electric blanket depends on how much the blanket is used. As a general rule, you should wash the blanket when you think it needs it. You may need to wash it infrequently if it is on a bed that doesn't often get used, or if you're a nightly user, you might prefer to get in a routine of washing the blanket each time you wash your other bedding. If you plan to pack away the blanket, wash it before putting it in storage.
When you shouldn't wash a heated blanket
Do not wash a heated blanket that still has any cords attached. Additionally, if the blanket's care instructions suggest hand washing instead of machine washing, do not wash the blanket in the washing machine.
How to get rid of stains on a heated blanket
If you use your electric blanket a lot, it's inevitable that, eventually, you'll need to treat a stain or two. In most cases, a regular washing process will do, but when it won't, try mixing some laundry detergent and warm water and pretreating. Using a clean cloth, apply the soapy water mixture to the stain. You can either leave that setting and then wash the blanket following its care instructions or rinse the stain-treated area with another damp cloth and then air dry.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

Yahoo

time18 minutes ago

  • Yahoo

Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

Tividenofusp alfa BLA for Hunter syndrome accepted for priority review and assigned PDUFA target action date of January 5, 2026; company preparing for commercial launch DNL126 accelerated approval path for Sanfilippo syndrome Type A aligned with FDA; Phase 1/2 study nearing completion of enrollment; planning underway for a global Phase 3 confirmatory study On track to submit regulatory applications in 2025 to begin clinical testing of one to two additional TransportVehicleTM (TV)-enabled programs Preclinical research on ATV:Abeta program for Alzheimer's disease published in the journal Science SOUTH SAN FRANCISCO, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the second quarter ended June 30, 2025, and provided business highlights. 'The FDA's priority review of our BLA for tividenofusp alfa and alignment on an accelerated approval path for DNL126 are key milestones highlighting the potential of our Transport Vehicle (TV) platform to catalyze a new class of blood-brain barrier-crossing therapeutics,' said Ryan Watts, Ph.D., CEO of Denali Therapeutics. 'With launch readiness in motion and a growing portfolio of TV-enabled enzyme, antibody, and oligonucleotide programs, Denali is poised to deliver meaningful treatments for people living with lysosomal, neurodegenerative, and other serious diseases.' Second Quarter 2025 and Recent Program Updates CLINICAL PROGRAMS Tividenofusp alfa (DNL310, ETV:IDS) for Hunter syndrome (MPS II) In July 2025, Denali announced that the U.S. Food and Drug Administration (FDA) accepted its Biologics License Application (BLA) for tividenofusp alfa for priority review, assigning a Prescription Drug User Fee Act (PDUFA) target action date of January 5, 2026. The BLA seeks accelerated approval based on a data package including results from the Phase 1/2 study in individuals with Hunter syndrome. Tividenofusp alfa is an investigational, next-generation enzyme replacement therapy designed to cross the blood-brain barrier (BBB) and deliver the iduronate-2-sulfatase (IDS) enzyme throughout the body and brain. The FDA previously granted tividenofusp alfa Breakthrough Therapy, Fast Track, Orphan Drug, and Rare Pediatric Disease designations. Denali continues to prepare for commercial launch and is conducting the Phase 2/3 COMPASS study to support global regulatory submissions. DNL126 (ETV:SGSH) for Sanfilippo syndrome type A (MPS IIIA) Today, Denali announced that it has reached alignment with the FDA's Center for Drug Evaluation and Research (CDER) that cerebrospinal fluid heparan sulfate (CSF HS) may be considered a reasonably likely surrogate endpoint to predict clinical benefit and may therefore be used to support accelerated approval of DNL126 for MPS IIIA. Additional 49-week data from the ongoing open-label Phase 1/2 study are consistent with previously announced 25-week data, demonstrating a significant reduction in CSF HS from baseline, including normalization, and a safety profile that supports continued development. Enrollment in the Phase 1/2 study is nearly complete, and planning is underway for a confirmatory global Phase 3 study. TAK-594/DNL593 (PTV:PGRN) for GRN-related frontotemporal dementia Denali and Takeda continue their collaboration to develop DNL593, an investigational therapeutic designed to deliver progranulin across the BBB for the treatment of granulin (GRN) mutation-associated frontotemporal dementia (FTD-GRN). A Phase 1/2 study is ongoing. BIIB122/DNL151 (small molecule LRRK2 inhibitor) for the treatment of Parkinson's disease (PD) Denali and Biogen are co-developing LRRK2 inhibitors for Parkinson's disease. In May 2025, Biogen announced that the Phase 2b LUMA study of BIIB122 completed enrollment, with a readout expected in 2026. Denali is also conducting the Phase 2a BEACON study focused on LRRK2-associated PD. IND-ENABLING STAGE PROGRAMS Denali expects to submit regulatory applications to begin clinical testing of one to two TV-enabled programs each year over the next three years across its Enzyme TV (ETV), Antibody TV (ATV), and Oligonucleotide TV (OTV) franchises. The most advanced programs include: DNL952 (ETV:GAA) for Pompe disease; DNL111 (ETV:GCase) for Parkinson's/Gaucher disease; DNL622 (ETV:IDUA) for MPS I; DNL921 (ATV:Abeta) for Alzheimer's disease; DNL628 (OTV:MAPT) for Alzheimer's disease; and DNL422 (OTV:SNCA) for Parkinson's disease. Denali announced publication of preclinical data on ATV:Abeta in the August 7, 2025, issue of the journal Science. The research demonstrated that delivering an anti-amyloid beta antibody across the BBB using Denali's TV platform improved brain distribution and reduced the risk of amyloid-related imaging abnormality (ARIA) in a mouse model of Alzheimer's disease, compared to conventional antibody treatment. The findings suggest that TV platform-enabled brain delivery of immunotherapy bypasses amyloid-laden large vessels by traveling through smaller capillaries, offering a potential strategy to mitigate ARIA risk seen with first-generation anti-amyloid therapies. The Science article can be accessed here. Participation in Upcoming Investor Conferences Cantor Global Healthcare Conference 2025, September 3 - 5 (New York City) Morgan Stanley 23rd Annual Global Healthcare Conference, September 8 - 10 (New York City) Baird 2025 Global Healthcare Conference, September 9 - 10 (New York City) H.C. Wainwright 27th Annual Global Investment Conference, September 8 - 10 (New York City) Deutsche Bank BioPharm Corporate Day, September 18 - 19 (Austria) Stifel 2025 Healthcare Conference, November 11 - 13 (New York City) Jefferies Global Healthcare Conference, November 17 - 20 (London) Second Quarter 2025 Financial Results Net loss was $124.1 million for the quarter ended June 30, 2025, compared to net loss of $99.0 million for the quarter ended June 30, 2024. Total research and development expenses were $102.7 million for the quarter ended June 30, 2025, compared to $91.4 million for the quarter ended June 30, 2024. The increase of approximately $11.3 million was attributable to an increase of $7.3 million in TV program external research and development expenses, primarily driven by increased spend on multiple preclinical programs, and increases of $7.6 million and $6.2 million in other research and development expenses and personnel-related expenses, respectively, both driven by the commencement of operations at Denali's large molecule manufacturing facility in Salt Lake City, Utah. These increases were partially offset by a $9.8 million decrease in small molecule programs, primarily due to the winding down of activities related to the Phase 2/3 HEALEY ALS Platform Trial. General and administrative expenses were $32.3 million for the quarter ended June 30, 2025, compared to $25.2 million for the quarter ended June 30, 2024. The increase of $7.1 million was primarily driven by activities related to preparations for a potential commercial launch for tividenofusp alfa. Cash, cash equivalents, and marketable securities were approximately $977.4 million as of June 30, 2025. About Denali Therapeutics Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. Denali pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the BBB, and guiding development through biomarkers that demonstrate target and pathway engagement. Denali is based in South San Francisco. For additional information, please visit Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding expectations for Denali's TV platform and its therapeutics and commercial potential; statements made by Denali's Chief Executive Officer; plans, timelines, and expectations relating to DNL310, including the PDUFA target action date and the timing, likelihood of, and scope of regulatory approval, the ongoing global Phase 2/3 COMPASS study and the likelihood of global approvals, and planned commercial launch; plans, timelines, and expectations related to DNL126, including enrollment in the ongoing Phase 1/2 study, plans regarding the confirmatory global Phase 3 study, planned engagement with the FDA, and the likelihood and scope of regulatory approvals; plans regarding DNL593 and the ongoing Phase 1/2 study; plans, timelines, and expectations regarding DNL151, including with respect to the ongoing Phase 2b LUMA study and the timing and likelihood of readout, and the ongoing Phase 2a BEACON study; plans and expectations for Denali's preclinical programs, including the timing of advancement to clinical studies; the findings from Denali's recent Science publication and their therapeutic potential regarding ARIA risk; Denali's participation in upcoming investor conferences; and Denali's future operating expenses and anticipated cash runway. All drugs currently being developed by Denali are investigational and have not received regulatory approval for any indication. Actual results are subject to risks and uncertainties and may differ materially from those indicated by these forward-looking statements as a result of these risks and uncertainties, including but not limited to, risks related to: the impact of adverse economic conditions, tariffs, and inflation on Denali's business and operations; the occurrence of any event, change, or other circumstance that could give rise to the termination of Denali's agreements with Sanofi, Takeda, Biogen, or other collaborators; Denali's transition to a late-stage clinical drug development company; Denali's and its collaborators' ability to complete the development and, if approved, commercialization of its product candidates; Denali's and its collaborators' ability to enroll patients in its ongoing and future clinical trials; Denali's reliance on third parties for the manufacture and supply of its product candidates for clinical trials; Denali's dependence on successful development of its blood-brain barrier platform technology and its programs and product candidates; Denali's and its collaborators' ability to conduct or complete clinical trials on expected timelines; the risk that preclinical profiles of Denali's product candidates may not translate in clinical trials; the potential for clinical trials to differ from preclinical, early clinical, preliminary or expected results; the risk of significant adverse events, toxicities, or other undesirable side effects; the uncertainty that product candidates will receive regulatory approval necessary to be commercialized; Denali's ability to continue to create a pipeline of product candidates or commercialize products; developments relating to Denali's competitors and its industry, including competing product candidates and therapies; Denali's ability to obtain, maintain, or protect intellectual property rights related to its product candidates; implementation of Denali's strategic plans for its business, product candidates, and blood-brain barrier platform technology; Denali's ability to obtain additional capital to finance its operations, as needed; Denali's ability to accurately forecast future financial results and hedge against financial risk in the current environment; and other risks and uncertainties, including those described in Denali's most recent Annual Report and Quarterly Reports on Forms 10-K and 10-Q filed with the Securities and Exchange Commission (SEC) on February 27, 2025 and May 6, 2025, and Denali's future reports to be filed with the SEC. Denali does not undertake any obligation to update or revise any forward-looking statements, to conform these statements to actual results, or to make changes in Denali's expectations, except as required by law. Denali Therapeutics Consolidated Statements of Operations(Unaudited)(In thousands, except share and per share amounts) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Operating expenses: Research and development $ 102,696 $ 91,399 218,923 198,415 General and administrative 32,267 25,194 61,620 50,430 Total operating expenses 134,963 116,593 280,543 248,845 Gain from divestiture of small molecule programs — — — 14,537 Loss from operations (134,963 ) (116,593 ) (280,543 ) (234,308 ) Interest and other income, net 10,844 17,567 23,454 33,480 Net loss $ (124,119 ) $ (99,026 ) $ (257,089 ) $ (200,828 ) Net loss per share, basic and diluted $ (0.72 ) $ (0.59 ) $ (1.50 ) $ (1.26 ) Weighted average number of shares outstanding, basic and diluted 171,449,847 168,831,329 171,336,568 159,117,759 Denali Therapeutics Consolidated Balance Sheets(Unaudited)(In thousands) June 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 141,207 $ 174,960 Short-term marketable securities 757,745 657,371 Prepaid expenses and other current assets 35,754 32,105 Total current assets 934,706 864,436 Long-term marketable securities 78,463 359,373 Property and equipment, net 58,717 55,236 Finance lease right-of-use asset 50,363 47,533 Operating lease right-of-use asset 21,022 22,861 Other non-current assets 22,970 24,741 Total assets $ 1,166,241 $ 1,374,180 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 10,844 $ 11,137 Accrued compensation 12,068 24,728 Accrued clinical and other research & development costs 23,379 22,822 Accrued manufacturing costs 9,028 12,779 Operating lease liability, current 8,871 8,308 Deferred research and development funding liability, current 19,861 14,129 Other accrued costs and current liabilities 7,006 8,305 Total current liabilities 91,057 102,208 Operating lease liability, less current portion 32,110 36,673 Finance lease liability, less current portion 5,577 5,615 Deferred research funding and development liability, less current portion 10,444 — Total liabilities 139,188 144,496 Total stockholders' equity 1,027,053 1,229,684 Total liabilities and stockholders' equity $ 1,166,241 $ 1,374,180 Investor Contact:Laura Hansen, Media Contact:Erin Pattonepatton@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Laxxon Medical Announces Successful Product Development Milestone with Novel Oral Modified-Release Formulation of Veru's Enobosarm, Utilizing Laxxon's SPID®-Technology
Laxxon Medical Announces Successful Product Development Milestone with Novel Oral Modified-Release Formulation of Veru's Enobosarm, Utilizing Laxxon's SPID®-Technology

Yahoo

time18 minutes ago

  • Yahoo

Laxxon Medical Announces Successful Product Development Milestone with Novel Oral Modified-Release Formulation of Veru's Enobosarm, Utilizing Laxxon's SPID®-Technology

NEW YORK, August 11, 2025--(BUSINESS WIRE)--Laxxon Medical Corp., a leading pharmaceutical technology company pioneering a new generation of advanced oral drug delivery systems, today announced that Veru Inc. (NASDAQ: VERU), a late clinical-stage biopharmaceutical company advancing treatments for cardiometabolic and inflammatory diseases, has selected a novel modified-release oral formulation of enobosarm that will utilize Laxxon's proprietary SPID® (Screen Printing Innovation Drug)-Technology. The novel tablet formulation achieved the desired target release profile, including a reduced maximum plasma concentration (Cmax), a delayed time to maximum plasma concentration (Tmax), a distinct secondary peak plasma concentration, and a similar extent of absorption (AUC) compared to historical values for immediate release enobosarm capsules. "This milestone underscores the strength of our SPID®-Technology in enhancing bioavailability and optimizing drug release profiles," said Helmut Kerschbaumer, Chief Executive Officer of Laxxon Medical. "The collaboration with Veru reflects our commitment to advancing next-generation drug formulations, and we are excited to support them on their product development pathway." Sequential release of APIs, processing of molecules like peptides in combination with permeation enhancers, processing of nanoparticles, multi-compartment tablets starting at a micro-tablet dimension as small as < 750 micron, are just some of the various possibilities which SPID®-Technology enables, and multiple other functionalities can be combined in one tablet with the potential upscaling from lab to mass production. "Selecting Laxxon as our formulation development partner was a strategic decision, driven by the strength of their SPID® platform and their proven expertise in advanced drug formulation," said Mitchell Steiner, M.D., Chairman, President, and Chief Executive Officer of Veru. "The resulting modified-release oral formulation of enobosarm has multiple benefits when treating the intended patient population and represents a significant advance over conventional drug product dosage forms as we move towards Phase 3 clinical trials and potential commercialization, pending regulatory approval." About Laxxon MedicalLaxxon Medical Corp. is a leading pharma-technology company and global leader of smart drug delivery systems in the pharmaceutical industry, pioneering a new generation of advanced pharmaceuticals designed to optimize drug delivery and maximize patient success through SPID®-Technology, Laxxon's proprietary screen printing technology platform. SPID®-Technology unlocks innovative drug delivery advancements paired with fast-tracked market access and extensive IP protection to yield disruptive opportunities in drug development and commercialization. With SPID®-Technology, Laxxon can develop and manufacture advanced versions of new and existing pharmaceutical drugs while extending and adding new patent protection through the technology transfer process. Laxxon can fully utilize the FDA's 505b(2) regulatory pathway in the US and Hybrid applications under article 10(3) of Directive 2001/83/EC in the EU, which fast tracks product routes to market. Laxxon's pipeline includes ongoing working-projects with notable pharma players, biotech companies and research universities, in addition to 13 in-house Advanced Patented Generics products. Laxxon's IP is continuously growing, and together with the licensed IP from Exentis Group, consists of >230 patents and patent applications with more than 5,000 patent claims. About Veru Inc. is a late clinical-stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases. The Company's drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator (SARM), is being developed as a next generation drug that makes weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, thereby improving body composition and physical function. Sabizabulin, a microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease. For more information, visit View source version on Contacts Laxxon Investor and Media Contacts: IR@ Veru Investor and Media Contact: Samuel FischExecutive Director, Investor Relations and Corporate CommunicationsEmail: veruinvestor@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Husband's demand for ‘me time' after ‘stressful' work day scrutinized by stay-at-home-mom sympathizers: ‘Can you buck up?'
Husband's demand for ‘me time' after ‘stressful' work day scrutinized by stay-at-home-mom sympathizers: ‘Can you buck up?'

New York Post

time19 minutes ago

  • New York Post

Husband's demand for ‘me time' after ‘stressful' work day scrutinized by stay-at-home-mom sympathizers: ‘Can you buck up?'

Working six days a week in healthcare isn't exactly a picnic — but one husband's plea for 'me time' after his grueling shifts has sparked a Reddit uproar in defense of his stay-at-home wife's nonstop kid-wrangling gig. The man, a dad of three — ages nine, six and two — recently spilled his burnout woes on Reddit's AITAH [Am I The A—hole?] forum. 'I work in healthcare, so I can have pretty full-on/stressful days and can often feel very emotionally as well as physically drained when I get home from work and have been feeling increasingly burnt out recently.' Advertisement The dad of three (ages nine, six, and two) recently vented his burnout blues on Reddit's AITAH forum — and the internet's reaction was anything but unanimous. Studio Romantic – After long, stressful days, he claimed he's running on empty. 'I find I can function at work to get the job done, but once I'm home, I've got nothing in the tank, which leads to having very little patience and really only being present in body only,' he wrote. His only 'me time,' he explained, is the commute home and a rare weekly run, with post-bedtime doom-scrolling and TV binges to recharge. The real kicker? He's expected to tag-team with wifey to wrestle with his little rascals as soon as he enters the ring. Advertisement The man asked bluntly, 'AITAH [am I the a—hole] for wanting some me time when I get home?' Reddit users were quick to weigh in — and it wasn't a unanimous cheer squad. 'Can you get a sitter or someone to watch the kids for 1-2 days a week?' one practical soul suggested. Another dropped marriage counselor wisdom: 'The solution was for him to have 10-15 minutes decompression time when he got in from work. But once that time was up, he had to do whatever she needed him to do.' Advertisement Some users, however, served a cold dose of reality. Looks like when it comes to parenting burnout, it's not just about clocking hours — it's about sharing the load. And maybe 'me time' is a team sport. Elnur – 'I'm a physician (F). My ex-wife raised our 2 kids while I did a very stressful job… So I guess you signed up for having kids? Do you want someone else to raise them? Can you buck up and realize you are all in? … You need to understand that it's a sacrifice and it won't be forever.' Advertisement Others called out the dad for overlooking his wife's nonstop 24/7 grind. 'NTA [not the a—hole] for now, but leaning towards YTA [you're the a—hole]. What breaks does the stay-at-home Mom get? What adult interaction does she get? Does she have a commute to decompress? Does she get ME time?' 'You get vacation time… when is hers? Not only is she raising kids, she's managing the house, cooking, cleaning and mental load… Grow up and be a partner.' Still, some offered a middle ground. 'NTA for wanting a little me time, but you also have to think about your wife's me time too. Talk to her… maybe call a sitter, schedule her a spa day during your work hours and let her have her me time that day and have your me time the day after… You guys have to communicate and compromise.' As previously reported by The Post, today's busy parents are finding creative ways to make every second count with their kids — like millennial stay-at-home mom Sara Martinez, who went viral with the '9-minute theory,' spotlighting three key three-minute windows a day when parental presence matters most. From Upper West Side entrepreneurs hiring help to moms moving off the grid for quality time, parents are reshaping the rules on how to balance burnout and bonding — proving that sometimes, it's less about quantity and more about making moments count.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store